Diabetes Prevention Clinical Trials

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept ...

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy ...

Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's ability to produce insulin decreases. ...

Type 2 Diabetes? Currently using Insulin? Such as Levemir ®, Lantus®, Humulin N®, Novolin N®, Basaglar®, or other long- acting insulin You may be eligible to participate in a 58 week Research Study if you are: Diagnosed with Type 2 Diabetes Currently using insulin Age 18 or older ClinicalTrials.gov Identifier: ...

Have you been diagnosed with Prediabetes or Type II Diabetes? Are you treating your condition with diet or metformin alone? A clinical research study is being conducted by Dr. John E. Ervin at The Center for Pharmaceutical Research. The outpatient study is testing an investigational weight loss device intended to ...

The overall study will consist of two parts conducted in tandem: This Pilot Study is a 3-month pilot RCT study to test the feasibility of the Sweetch app in combination with a digital body weight scale (DBWS), with both groups receiving usual care for prediabetes.

Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular permeability including diabetic macular edema (DME). While there is strong evidence that PDR outcomes are markedly reduced in eyes that are treated ...

Following written consent, all study patients will undergo the following clinical, metabolic and laboratory evaluations before and during treatment. To ensure that patients remain unidentified, all study subjects will be assigned an individual study identifier which includes the study acronym, patient initials, and unique number. All blood samples will be ...

This is a single center 12-week Pilot trial with one arm. Subjects will serve as their own controls. The study will include usual care patients on MDI (multiple daily injections) or CSII (continuous subcutaneous insulin infusion) with the additional use of the Vigilant ™ Diabetes Management System. There will be ...

A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study. The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed640G and SmartGuardin preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion therapy in type 1 diabetes adults with an increased risk of hypoglycemia. The ...